Healthcare
Satellos Bioscience Inc. Common Stock(MSLE)
Live Price
Offline$5.71
-2.39% today
1Y Change
+9.39%
Window
Jun 25, 2025 β Jun 18, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +228.2%
- Dividend Yield
- 0.0%
Coverage: 247 bars Β· Jun 25, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Satellos Bioscience Inc. Common Stock (MSLE) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $5.71 and up 9.4% across the available one-year price window (Jun 25, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +228.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +228.2%, free cash flow 0.0% with operating margin 0.0% and ROIC -20.7%. Stock Foundry combines MSLE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +228.2%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | β | +0.3% | -3.7% | -19.0% |
2026 Mar 27, 2026 | -30.6% | -4.5% | -8.7% | +15.7% |
2025 Nov 14, 2025 | -11.1% | +9.6% | -1.8% | -5.7% |
Benchmark Edge
MSLE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MSLE
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MSLE Max Drawdown
-57.03%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MSLE and SPY.
Company Overview
Satellos Bioscience Inc. Common Stock
NASDAQ Global Market
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenXβ’ and Leveraging MyoReGenXβ’, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
- Leadership
- Francis Gleeson
- IPO Date
- May 10, 2024
- Employees
- 14
- Street Address
- Royal Bank Plaza
- Mailing
- Toronto, ON, M5J 2J1
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 1 647 660 1780
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- 0.5
Growth
- Revenue
- 0.0%
- EPS
- +228.2%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -51.4%
- ROIC
- -20.7%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 11.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.